HYDROXYCHLOROQUINE SULFATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H26ClN3O.H2O4S
Molecular Weight	433.95
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2

InChI

InChIKey=JCBIVZZPXRZKTI-UHFFFAOYSA-N

InChI=1S/C18H26ClN3O.H2O4S/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18;1-5(2,3)4/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21);(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C18H26ClN3O
Molecular Weight	335.872
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01611
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf

Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. Although the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter DNA. Hydroxychloroquine has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown. Hydroxychloroquine is used for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Toll-like receptor 7 12 Target ID: CHEMBL5936 Sources: http://www.drugbank.ca/drugs/DB01611	Antagonist 2778		2.78 µM [IC50]
Toll-like receptor 9 4 Target ID: CHEMBL5804 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24342772	Antagonist 2778		0.08 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Malaria 95 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf	Curative	Approved 8429	PLAQUENIL Approved Use PLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. Launch Date 1955
Systemic lupus erythematosus 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf	Primary	Approved 8429	PLAQUENIL Approved Use PLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. Launch Date 1955
Rheumatoid arthritis 316 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf	Primary	Approved 8429	PLAQUENIL Approved Use PLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. Launch Date 1955

C_max

Value	Dose	Analyte	Population
129.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.22 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
50.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
102.3 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
537 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
172.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2963 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
48% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8359187	unknown, unknown		HYDROXYCHLOROQUINE SULFATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	Other AEs: Cardio-respiratory arrest... Other AEs: Cardio-respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/
200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine aspirin ibuprofen Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	Other AEs: Tachycardia, Hypotension... Other AEs: Tachycardia Hypotension Depression Hypokalemia Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/
20 g 1 times / day single, oral Studied dose Dose: 20 g, 1 times / day Route: oral Route: single Dose: 20 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	healthy, 18 years n = 1 Health Status: healthy Age Group: 18 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	Other AEs: Hypotension, Hypokalemia... Other AEs: Hypotension Hypokalemia Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/
12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	healthy, 2.5 years n = 1 Health Status: healthy Age Group: 2.5 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	Other AEs: Cardio-respiratory arrest... Other AEs: Cardio-respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/
4 g 1 times / day single, oral Studied dose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	healthy, 29 years n = 1 Health Status: healthy Age Group: 29 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/	Other AEs: Vomiting, Ventricular tachycardia... Other AEs: Vomiting Ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/11555803/
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	DLT: Nausea, Vomiting... Other AEs: Lymphopenia, Anemia... Dose limiting toxicities: Nausea (grade 3, 13%) Vomiting (grade 3, 13%) Other AEs: Lymphopenia (grade 3-4, 13%) Anemia (grade 1-2, 13%) Thrombocytopenia (grade 1-2, 13%) Anorexia (grade 1-2, 38%) Bradycardia (grade 1-2, 13%) Constipation (grade 1-2, 25%) Diarrhea (grade 1-2, 25%) Fatigue (grade 1-2, 88%) Hypotension (grade 1-2, 13%) Nausea (grade 1-2, 50%) Rash (grade 1-2, 13%) Vomiting (grade 1-2, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/
200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	unhealthy, median age 64 years n = 15 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	DLT: Heart block... Dose limiting toxicities: Heart block (grade 3, 6.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/
500 mg 2 times / day multiple, oral Studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	unhealthy, median age 64 years n = 7 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/	DLT: Rash... Dose limiting toxicities: Rash (grade 3, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/24991839/
200 mg 2 times / day steady, oral Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01537315	unhealthy n = 7 Health Status: unhealthy Condition: cardiovascular disease Population Size: 7 Sources: https://clinicaltrials.gov/ct2/show/NCT01537315	Other AEs: Increased blood pressure... Other AEs: Increased blood pressure (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01537315

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C8 693 CYP3A5 395

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1891	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015042/	yes		yes (co-administration study) Comment: Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 ± 4.6%) and maximal plasma concentrations (72 ± 6.9%) of metoprolol Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015042/

Drug as victim

Target	Modality	Activity
CYP2C8 693	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/art.39402; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600351/	likely
CYP2D6 1217	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/art.39402; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600351/	likely
CYP3A4 1737	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/art.39402; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600351/	likely
CYP3A5 395	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/art.39402; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600351/	likely

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/33674391/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5801	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5801
ChemicalBook	CB6866802	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6866802
MolPort	MolPort-003-847-792	https://www.molport.com/shop/molecule-link/MolPort-003-847-792
eMolecules	901965	https://www.emolecules.com/cgi-bin/more?vid=901965

PubMed

Title	Date	PubMed
[Amphiphilic cationic drug myopathy, drug-induced lysosomal storage lipidosis].	2001	11596386
Management of hepatitis C virus-related arthritis.	2001	11580301
Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis.	2001	11543695
Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.	2001 Apr	11354305
Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.	2001 Apr-Jun	11403336
Early hydroxychloroquine macular toxicity.	2001 Aug	11508449
Bromocriptine in rheumatic and autoimmune diseases.	2001 Aug	11503136
Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study.	2001 Aug 11	11513909
Systemic lupus erythematosus: current management.	2001 Aug 6	11548075
[Combined basic therapeutic drugs. From individual hope to targeted use].	2001 Dec	11826745
Hydroxychloroquine retinopathy.	2001 Dec	11733247
A linear erythema on the nose of a Korean girl.	2001 Feb	11320704
Treating early rheumatoid arthritis in the younger patient.	2001 Jun	11409156
Conventional DMARD options for patients with a suboptimal response to methotrexate.	2001 Jun	11409154
Rheumatologists' attitudes toward routine screening for hydroxychloroquine retinopathy.	2001 Jun	11409112
Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?	2001 Jun	11384574
Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre.	2001 Jun	11350849
Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction.	2001 Jun 1	11359853
The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea.	2001 Jun 15	11377382
[Photodermatosis induced by hydroxychloroquine: 4 cases].	2001 Jun-Jul	11460035
Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus.	2001 Mar	11495297
Management of a patient with sarcoid calcaneitis and dactylitis.	2001 Mar	11324935
Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report.	2001 May	11480331
Lupus profundus, indeterminate lymphocytic lobular panniculitis and subcutaneous T-cell lymphoma: a spectrum of subcuticular T-cell lymphoid dyscrasia.	2001 May	11401667
Combination therapy in rheumatoid arthritis.	2001 May	11333345
Dermatomyositis.	2001 Nov 1	11730311
[Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].	2001 Nov-Dec	11865567
Verrucous form of chilblain lupus erythematosus.	2001 Sep	11763388
Treatment of hydroxychloroquine overdose.	2001 Sep	11555803
Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.	2001 Sep	11550982
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.	2001 Sep 8	11564493
Dermatomyositis and Graves' disease.	2001 Sep-Oct	11579725
Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus.	2002	11898921
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.	2002 Apr	11953964
Canadian Consensus Conference on hydroxychloroquine.	2002 Apr	11950041
Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis.	2002 Apr	11950006
Pharmacoeconomics of long-term treatment of rheumatoid arthritis.	2002 Apr	11934345
[Primary Gougerot-Sjögren syndrome in a 13-year-old girl].	2002 Feb	11915495
How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy?	2002 Feb	11840465
Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.	2002 Feb	11838842
Antimalarial agents in pregnancy.	2002 Feb 9	11853823
Second-line drugs used in recent-onset rheumatoid arthritis in Brittany (France).	2002 Jan	11858354
Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells.	2002 Jan	11849318
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.	2002 Jan	11824975
Leflunomide induced fevers, thrombocytosis, and leukocytosis in a patient with relapsing polychondritis.	2002 Jan	11824960
Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis.	2002 Jan 11	11738695
IgM antibodies against cytomegalovirus in SLE nephritis: viral infection or aspecific autoantibody?	2002 Jan-Feb	11936434
Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.	2002 Mar	11916085
Nonendemic pemphigus foliaceus in children.	2002 Mar	11862179
The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.	2002 Mar	11850097

Patents

Sample Use Guides

In Vivo Use Guide

Malaria: Suppression— In adults, 400 mg (=310 mg base) on exactly the same day of each week. In infants and children, the weekly suppressive dosage is 5 mg, calculated as base, per kg of body weight, but should not exceed the adult dose regardless of weight.

Route of Administration: Oral

In Vitro Use Guide

After 48 hours of stimulation with PMA and ionomycin, Hydroxychloroquine (25-100 uM) inhibited the production of IL-6, IL-17 and IL-22 in the PBMCs of healthy volunteers

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:13:55 GMT 2023` Edited by `admin` on `Fri Dec 15 15:13:55 GMT 2023`
Record UNII	8Q2869CNVH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROXYCHLOROQUINE SULFATE

Common Name

English

HYDROXYCHLOROQUINE SULPHATE

Common Name

English

PLAQUENIL SULFATE

Brand Name

English

HYDROXYCHLOROQUINE SULFATE [JAN]

Common Name

English

HYDROXYCHLOROQUINE SULFATE [EP MONOGRAPH]

Common Name

English

NSC-4375

Code

English

(±)-2-((4-((7-CHLORO-4-QUINOLYL)AMINO)PENTYL)ETHYLAMINO)ETHANOL SULFATE (1:1) (SALT)

Common Name

English

HYDROXYCHLOROQUINE SULFATE [USP MONOGRAPH]

Common Name

English

HYDROXYCHLOROQUINE SULFATE [MART.]

Common Name

English

Hydroxychloroquine sulfate [WHO-DD]

Common Name

English

ERCOQUIN

Brand Name

English

ETHANOL, 2-((4-((7-CHLORO-4-QUINOLINYL)AMINO)PENTYL)ETHYL)AMINO-, (±)-, SULFATE (1:1) SALT

Common Name

English

HYDROXYCHLOROQUINE SULFATE [MI]

Common Name

English

HYDROXYCHLOROQUINE SULFATE [VANDF]

Common Name

English

HYDROXYCHLOROQUINE SULFATE [USP-RS]

Common Name

English

HYDROXYCHLOROQUINE SULFATE [ORANGE BOOK]

Common Name

English

OXIKLORIN

Brand Name

English

ETHANOL, 2-((4-((7-CHLORO-4-QUINOLINYL)AMINO)PENTYL)ETHYL)AMINO-, (±)-, SULPHATE (1:1) SALT

Common Name

English

(±)-2-((4-((7-CHLORO-4-QUINOLYL)AMINO)PENTYL)ETHYLAMINO)ETHANOL SULPHATE (1:1) (SALT)

Common Name

English

QUENSYL

Brand Name

English

PLAQUENIL

Brand Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/17/1963